Bisoprolol: Clinical Overview
Bisoprolol is a cardioselective β1-blocker indicated primarily for heart failure with reduced ejection fraction (HFrEF) and hypertension, with proven mortality reduction in HFrEF when titrated to target doses. 1
Primary Indications
Heart Failure with Reduced Ejection Fraction (HFrEF)
- LVEF ≤40% with NYHA class II-IV symptoms 2, 3, 1
- Bisoprolol is one of only three β-blockers with proven mortality benefit (along with carvedilol and metoprolol succinate) 3, 4
- Reduces all-cause mortality by 34% (NNT = 28 over 12 months) 1
- Also indicated for asymptomatic LV systolic dysfunction post-MI 2
Hypertension
- Approved for essential hypertension, though not recommended as first-line monotherapy unless compelling indications exist (IHD, post-MI, HFrEF) 5, 6
- ACE inhibitors, ARBs, dihydropyridine CCBs, and thiazide diuretics are preferred first-line agents 6
Stable Ischemic Heart Disease (SIHD)
- Indicated for stable angina and post-MI patients 7, 8
- Should be combined with ACE inhibitors or ARBs as guideline-directed medical therapy (GDMT) 8
Recommended Dosing
Initiation ("Start Low, Go Slow")
- Starting dose: 1.25 mg once daily 2, 3
- Must be clinically stable (no recent diuretic changes, not dependent on IV inotropes) 2
- Can be initiated cautiously pre-discharge in recently decompensated HF patients if improved and observed ≥24 hours 2
Titration Schedule
- Increase dose every 2-4 weeks if tolerated 2
- Doubling sequence: 1.25 mg → 2.5 mg → 5 mg → 10 mg once daily (target dose) 2, 1
- Monitor at each visit for:
- Worsening HF signs
- Symptomatic hypotension (dizziness)
- Excessive bradycardia (HR <50 bpm) 2
Target Dosing
- HFrEF target: 10 mg once daily 2, 1
- Minimum effective dose: ≥50% of target (5 mg daily) to achieve mortality benefit 9
- Mean dose achieved in clinical trials: 8.6 mg daily 1
Dose Adjustments
- Worsening HF during hospitalization: Reduce dose or temporarily discontinue; reinitiate before discharge 2
- Renal/hepatic impairment: Bisoprolol is cleared equally by kidneys and liver (50/50), making it safer than renally-cleared β-blockers in CKD 10, 11
Absolute Contraindications
Per FDA labeling and guidelines 12:
- Cardiogenic shock
- Overt cardiac failure (decompensated, requiring IV inotropes)
- Second- or third-degree AV block (without permanent pacemaker)
- Sick sinus syndrome (without pacemaker)
- Marked sinus bradycardia (HR <50 bpm) 2
Important: NOT Contraindicated
- COPD is NOT a contraindication 2, 13
- Bisoprolol is safe and effective in COPD, improving lung function (FEV1, FVC) and reducing inflammatory markers 13
- Cardioselectivity minimizes bronchospasm risk
- Asthma IS a contraindication 2
Monitoring Requirements
At Each Titration Visit (Every 2-4 Weeks)
- Heart rate: Hold if <50 bpm 2
- Blood pressure: Assess for symptomatic hypotension 2
- Clinical status: Signs of worsening HF (edema, dyspnea, weight gain) 2
Ongoing Monitoring
- Renal function and potassium: Especially when combined with ACE inhibitors/ARBs/aldosterone antagonists 4
- Blood glucose: May mask hypoglycemia symptoms in diabetics (though bisoprolol is safe in diabetes) 4, 11
- Liver enzymes: Sporadic elevations reported; monitor if clinically indicated 12
Common Adverse Effects
Dose-Related Effects (from FDA trials) 12:
- Fatigue/asthenia: 6.6-8.2% (vs 1.5% placebo)
- Bradycardia: 0.4-0.5%
- Diarrhea: 2.6-3.5%
- Dizziness: 2.9-3.5%
- Headache: 8.8-10.9%
Cardiovascular
- Hypotension (often improves with time; consider reducing other antihypertensives except ACE inhibitors) 2
- Cold extremities, claudication 12
- Congestive HF exacerbation (transient worsening may occur during initiation) 12
Metabolic
- Hyperkalemia: Particularly when combined with ACE inhibitors/ARBs/aldosterone antagonists 4
- Increased triglycerides: Most frequent lab abnormality (not consistent) 12
Other Notable Effects
- Bronchospasm: Rare due to β1-selectivity 12
- Sexual dysfunction: Decreased libido/impotence 12
- Depression, vivid dreams, insomnia 12
Rare but Serious (Post-Marketing)
- Angioedema, exfoliative dermatitis 12
- Cardiospasm (ROR≈285; novel signal from FAERS data) 14
- Palmoplantar keratoderma (ROR≈217; hypothesis-generating signal) 14
Withdrawal Rate
- Only 3.3% discontinued due to adverse events (vs 6.8% placebo) 12
- Never abruptly discontinue: Taper to avoid rebound hypertension/ischemia 5
Alternative Therapies
Other Evidence-Based β-Blockers for HFrEF
Carvedilol (non-selective β-blocker with α1-blockade)
Metoprolol succinate (extended-release)
Nebivolol (β1-selective with nitric oxide-mediated vasodilation)
When β-Blockers Are Contraindicated/Not Tolerated
- ACE inhibitors or ARBs: Foundational therapy for HFrEF (must be used unless contraindicated) 3, 1
- ARNI (sacubitril/valsartan): Superior to ACE inhibitors; 16% mortality reduction 1
- Aldosterone antagonists (spironolactone/eplerenone): Add for NYHA III-IV; 30% mortality reduction 2, 3, 1
- SGLT2 inhibitors (dapagliflozin/empagliflozin): 17% mortality reduction; safe with β-blockers 1
- Hydralazine + isosorbide dinitrate: Particularly for Black patients or ACE inhibitor-intolerant patients 3, 1
For Hypertension (Without HFrEF)
- First-line agents: ACE inhibitors, ARBs, thiazide diuretics, dihydropyridine CCBs 6
- β-blockers reserved for compelling indications (IHD, post-MI, HFrEF, rate control) 6
Critical Clinical Pearls
Pitfalls to Avoid
- Using non-evidence-based β-blockers: Only bisoprolol, carvedilol, and metoprolol succinate reduce mortality in HFrEF 4, 1
- Inadequate dose titration: Target doses achieve superior outcomes; aim for ≥50% of target 9, 1
- Premature discontinuation during HF hospitalization: Reduce dose rather than stop; reinitiate before discharge 2
- Avoiding β-blockers in COPD: COPD is NOT a contraindication; bisoprolol improves outcomes 2, 13
- Abrupt cessation: Always taper to prevent rebound phenomena 5
Special Populations
- Elderly (≥85 years): Continue lifelong if tolerated; slower titration acceptable 6
- Women: Bisoprolol equally effective; consider hormonal influences and pregnancy complications 15
- Diabetes: Safe; monitor for masked hypoglycemia 4, 11
- CKD: Preferred over renally-cleared β-blockers due to dual hepatic/renal clearance 10, 11
- Peripheral vascular disease: Not a contraindication; monitor for claudication 4
Combination Therapy Considerations
- With ACE inhibitors/ARBs: Synergistic benefit; monitor renal function and potassium 4
- With dihydropyridine CCBs: Safe for angina/hypertension; avoid non-dihydropyridines (verapamil/diltiazem) due to additive bradycardia 8
- Never combine with another β-blocker or dual RAS blockade (ACE inhibitor + ARB) 5